Search

Your search keyword '"Bottazzi, A"' showing total 443 results
Start Over Author "Bottazzi, A" Publisher elsevier bv
443 results on '"Bottazzi, A"'

3. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial

Author

Zinsou, Jeannot F, primary, Diemert, David J, additional, Dejon-Agobé, Jean Claude, additional, Adégbité, Bayodé R, additional, Honkpehedji, Yabo Josiane, additional, Vodonou, Kafui G, additional, Bikangui, Rodrigue, additional, Edoa, Jean Ronald, additional, Massinga Loembe, Marguerite, additional, Li, Guangzhao, additional, Yazdanbakhsh, Maria, additional, Bottazzi, Maria Elena, additional, van Leeuwen, Remko, additional, Kremsner, Peter G, additional, Hotez, Peter J, additional, Bethony, Jeffrey M, additional, Grobusch, Martin P, additional, and Adegnika, Ayola A, additional

Published
2024
Full Text
View/download PDF

5. Chagasin from Trypanosoma cruzi as a molecular scaffold to express epitopes of TSA-1 as soluble recombinant chimeras

Author

Cárdenas-Guerra, Rosa Elena, primary, Montes-Flores, Octavio, additional, Nava-Pintor, Edgar Ezequiel, additional, Reséndiz-Cardiel, Gerardo, additional, Flores-Pucheta, Claudia Ivonne, additional, Rodríguez-Gavaldón, Yasmín Irene, additional, Arroyo, Rossana, additional, Bottazzi, Maria Elena, additional, Hotez, Peter J., additional, and Ortega-López, Jaime, additional

Published
2024
Full Text
View/download PDF

6. Heterogeneous Mineralogical Composition and Fault Behaviour: A Systematic Study in Ternary Fault Rock Compositions

Author

Ruggieri, Roberta, primary, Pozzi, Giacomo, additional, Volpe, Giuseppe, additional, Francesca, Bottazzi, additional, Brignoli, Marco, additional, Corradi, Anna Antonia Irene, additional, Mantica, Stefano, additional, Petroselli, Stefania, additional, Osculati, Lorenzo, additional, Volontè, Giorgio, additional, and Collettini, Cristiano, additional

Published
2024
Full Text
View/download PDF

13. Vaccine value profile for Hookworm

Author

Puchner, Karl Philipp, primary, Bottazzi, Maria Elena, additional, Periago, Victoria, additional, Grobusch, Martin, additional, Maizels, Rick, additional, McCarthy, James, additional, Lee, Bruce, additional, Gaspari, Erika, additional, Diemert, David, additional, and Hotez, Peter, additional

Published
2023
Full Text
View/download PDF

14. Time to establish an international vaccine candidate pool for potential highly infectious respiratory disease: a community’s view

Author

Yao, Lan, primary, Chemaitelly, Hiam, additional, Goldman, Emanuel, additional, Gudina, Esayas Kebede, additional, Khalil, Asma, additional, Ahmed, Rahaman, additional, James, Ayorinde Babatunde, additional, Roca, Anna, additional, Fallah, Mosoka Papa, additional, Macnab, Andrew, additional, Cho, William C., additional, Eikelboom, John, additional, Qamar, Farah Naz, additional, Kremsner, Peter, additional, Oliu-Barton, Miquel, additional, Sisa, Ivan, additional, Tadesse, Birkneh Tilahun, additional, Marks, Florian, additional, Wang, Lishi, additional, Kim, Jerome H., additional, Meng, Xia, additional, Wang, Yongjun, additional, Fly, Alyce D., additional, Wang, Cong-Yi, additional, Day, Sara W., additional, Howard, Scott C., additional, Graff, J. Carolyn, additional, Maida, Marcello, additional, Ray, Kunal, additional, Franco-Paredes, Carlos, additional, Mashe, Tapfumanei, additional, Ngongo, Ngashi, additional, Kaseya, Jean, additional, Ndembi, Nicaise, additional, Hu, Yu, additional, Bottazzi, Maria Elena, additional, Hotez, Peter J., additional, Ishii, Ken J., additional, Wang, Gang, additional, Sun, Dianjun, additional, Aleya, Lotfi, additional, and Gu, Weikuan, additional

Published
2023
Full Text
View/download PDF

15. 115 The mannose-binding lectin (MBL) in MIS-C: relationship between MBL genotype, levels, and functional activity against SARS-CoV-2

Author

Stravalaci, Matteo, primary, Pagani, Isabel, additional, Zhong, Hang, additional, Sironi, Marina, additional, Bondesan, Simone, additional, Barzaghi, Federica, additional, Carrera, Paola, additional, Izzo, Francesca, additional, Zoia, Elena, additional, Bottazzi, Barbara, additional, Asselta, Rosanna, additional, Casari, Giorgio, additional, Aiuti, Alessandro, additional, Mantovani, Alberto, additional, and Garlanda, Cecilia, additional

Published
2023
Full Text
View/download PDF

17. The Lancet Commission on lessons for the future from the COVID-19 pandemic

Author

Jeffrey D Sachs, Salim S Abdool Karim, Lara Aknin, Joseph Allen, Kirsten Brosbøl, Francesca Colombo, Gabriela Cuevas Barron, María Fernanda Espinosa, Vitor Gaspar, Alejandro Gaviria, Andy Haines, Peter J Hotez, Phoebe Koundouri, Felipe Larraín Bascuñán, Jong-Koo Lee, Muhammad Ali Pate, Gabriela Ramos, K Srinath Reddy, Ismail Serageldin, John Thwaites, Vaira Vike-Freiberga, Chen Wang, Miriam Khamadi Were, Lan Xue, Chandrika Bahadur, Maria Elena Bottazzi, Chris Bullen, George Laryea-Adjei, Yanis Ben Amor, Ozge Karadag, Guillaume Lafortune, Emma Torres, Lauren Barredo, Juliana G E Bartels, Neena Joshi, Margaret Hellard, Uyen Kim Huynh, Shweta Khandelwal, Jeffrey V Lazarus, and Susan Michie

Subjects
SARS-CoV-2, COVID-19, Humans, General Medicine, Pandemics
Published
2022
Full Text
View/download PDF

18. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults

Author

David J, Diemert, Maria, Zumer, Doreen, Campbell, Shannon, Grahek, Guangzhao, Li, Jin, Peng, Maria, Elena Bottazzi, Peter, Hotez, and Jeffrey, Bethony

Subjects
Adult, Ancylostomatoidea, Vaccines, General Veterinary, General Immunology and Microbiology, Public Health, Environmental and Occupational Health, Aluminum Hydroxide, Antibodies, Neutralizing, Hookworm Infections, Immunogenicity, Vaccine, Lipid A, Infectious Diseases, Adjuvants, Immunologic, Immunoglobulin G, Tobacco, Animals, Humans, Molecular Medicine, Peptide Hydrolases
Abstract

The Necator americanus hemoglobinase, aspartic protease-1 (Na-APR-1), facilitates the ability of adult hookworms to parasitize the intestine of their human hosts. A recombinant version of APR-1 protected laboratory animals against hookworm infection by inducing neutralizing antibodies that block the protein's enzymatic activity and thereby impair blood feeding. A catalytically inactive version of the wild-type hemoglobinase (Na-APR-1(M74)) was expressed by infiltrating Nicotiana benthamiana tobacco plants with an Agrobacterium tumefaciens strain engineered to express the vaccine antigen, which was adjuvanted with aluminum hydroxide adjuvant (Alhydrogel).An open-label dose-escalation Phase 1 clinical trial was conducted in 40 healthy, hookworm-naïve adult volunteers in the United States. Participants received 30 or 100 µg of recombinant Na-APR-1(M74) with Alhydrogel or with Alhydrogel co-administered with one of two doses (2.5 or 5.0 µg) of an aqueous formulation of Glucopyranosyl Lipid A (GLA-AF). Intramuscular injections of study vaccine were administered on days 0, 56, and 112.Na-APR-1(M74)/Alhydrogel was well-tolerated; the most frequent adverse events were mild or moderate injection site tenderness and pain, and mild or moderate nausea and headache. No serious adverse events or adverse events of special interest related to vaccination were observed. Significantly higher levels of antigen-specific IgG antibodies were induced in those who received 100 µg Na-APR-1(M74) than those who received 30 µg of antigen. Adding GLA-AF to Na-APR-1(M74)/Alhydrogel resulted in higher levels of IgG against Na-APR-1(M74) in both the 30 and 100 µg Na-APR-1(M74) groups in comparison to the non-GLA formulations at the same antigen dose.Vaccination of hookworm-naïve adults with recombinant Na-APR-1(M74) was well-tolerated, safe, and induced significant IgG responses against the vaccine antigen Na-APR-1(M74). Given these favorable results, clinical trials of this product were initiated in hookworm-endemic areas of Gabon and Brazil.

Published
2022
Full Text
View/download PDF

19. Development of chimeric protein as a multivalent vaccine for human Kinetoplastid infections: Chagas disease and leishmaniasis

Author

Clímaco, Marianna de Carvalho, primary, de Figueiredo, Luiza Almeida, additional, Lucas, Rayane Cristina, additional, Pinheiro, Guilherme Rafael Gomide, additional, Dias Magalhães, Luísa Mourão, additional, Oliveira, Ana Laura Grossi de, additional, Almeida, Raquel Martins, additional, Barbosa, Fernando Sérgio, additional, Castanheira Bartholomeu, Daniella, additional, Bueno, Lilian Lacerda, additional, Mendes, Tiago Antonio, additional, Zhan, Bin, additional, Jones, Kathryn Marie, additional, Hotez, Peter, additional, Bottazzi, Maria Elena, additional, Oliveira, Fabrício Marcus Silva, additional, and Fujiwara, Ricardo Toshio, additional

Published
2023
Full Text
View/download PDF

21. Vaccines and therapeutics for immunocompromised patients with COVID-19

Author

Shoham, Shmuel, primary, Batista, Carolina, additional, Ben Amor, Yanis, additional, Ergonul, Onder, additional, Hassanain, Mazen, additional, Hotez, Peter, additional, Kang, Gagandeep, additional, Kim, Jerome H., additional, Lall, Bhavna, additional, Larson, Heidi J., additional, Naniche, Denise, additional, Sheahan, Timothy, additional, Strub-Wourgaft, Nathalie, additional, Sow, Samba O., additional, Wilder-Smith, Annelies, additional, Yadav, Prashant, additional, and Bottazzi, Maria Elena, additional

Published
2023
Full Text
View/download PDF

23. Heterologous mRNA-protein vaccination with Tc24 induces a robust cellular immune response against Trypanosoma cruzi, characterized by an increased level of polyfunctional CD8+ T-cells

Author

Poveda, Cristina, primary, Leão, Ana Carolina, additional, Mancino, Chiara, additional, Taraballi, Francesca, additional, Chen, Yi-Lin, additional, Adhikari, Rakesh, additional, Villar, Maria Jose, additional, Kundu, Rakhi, additional, Nguyen, Duc M., additional, Versteeg, Leroy, additional, Strych, Ulrich, additional, Hotez, Peter J., additional, Bottazzi, Maria Elena, additional, Pollet, Jeroen, additional, and Jones, Kathryn M., additional

Published
2023
Full Text
View/download PDF

26. Neonates undergoing pyloric stenosis repair are at increased risk of difficult airway management: secondary analysis of the NEonate and Children audiT of Anaesthesia pRactice IN Europe

Author

Disma, Nicola, primary, Engelhardt, Thomas, additional, Hansen, Tom G., additional, de Graaff, Jurgen C., additional, Virag, Katalin, additional, Habre, Walid, additional, Breschan, Christian, additional, Likar, Rudolf, additional, Platzer, Manuela, additional, Edelman, Isole, additional, Eger, Johanes, additional, Heschl, Stefan, additional, Messerer, Brigitte, additional, Vittinghof, Maria, additional, Kroess, Ruth, additional, Stichlberger, Martina, additional, Kahn, David, additional, Pirotte, Thierry, additional, Pregardien, Caroline, additional, Veyckemans, Francis, additional, Stevens, France, additional, Berghmans, Johan, additional, Bauters, Annemie, additional, De Baerdemaeker, Luc, additional, De Hert, Stefan, additional, Lapage, Koen, additional, Parashchanka, Aliaksandra, additional, Van Limmen, Jurgen, additional, Wyffels, Piet, additional, Lauweryns, Julie, additional, Najafi, Nadia, additional, Vundelinckx, Joris, additional, Butković, Diana, additional, Sorić, Ivana Kerovec, additional, Kralik, Sandra, additional, Markić, Ana, additional, Azman, Josip, additional, Markic, Josko, additional, Pupacic, Daniela, additional, Frelich, Michal, additional, Reimer, Petr, additional, Urbanec, René, additional, Cajková, Petra, additional, Mixa, Vladimír, additional, Sedláčková, Yvona, additional, Knoppová, Lenka, additional, Zlámalová (neé Květoňová), Alena, additional, Vavřina, Martin, additional, Žurek, Jiří, additional, Hansen, Tom, additional, Afshari, Arash, additional, Bille, Anders Bastholm, additional, Ellekvist, Marguerite, additional, Ilmoja, Mari-Liis, additional, Moor, Reet, additional, Kikas, Reet, additional, Väli, Merle, additional, Kallio, Kariantti, additional, Reponen, Elisa, additional, Suominen, Pertti, additional, Suvanto, Sami, additional, Vähätalo, Raisa, additional, Kokki, Hannu, additional, Kokki, Merja, additional, Harju, Jarkko, additional, Kokkonen, Miia, additional, Vieri, Jenni, additional, Manner, Tuula, additional, Catherine, Amory, additional, Ludot, Hugues, additional, Bert, Dina, additional, Godart, Juliette, additional, Laffargue, Anne, additional, Dupont, Hervé, additional, Urbina, Benjamin, additional, Baujard, Catherine, additional, Roulleau, Philippe, additional, Staiti, Giuseppe, additional, Bordes, Maryline, additional, Gaulain, Karine Nouette, additional, Hamonic, Yann, additional, Semjen, François, additional, Jacqmarcq, Olivier, additional, Lejus-Bourdeau Cécile Magne, Caroline, additional, Petry, Léa, additional, Ros, Lilica, additional, Zang, Aurélien, additional, Bennis, Mehdi, additional, Coustets, Bernard, additional, Fesseau, Rose, additional, Constant, Isabelle, additional, Khalil, Eliane, additional, Sabourdin, Nada, additional, Audren, Noemie, additional, Descarpentries, Thomas, additional, Fabre, Fanny, additional, Legrand, Aurélien, additional, Druot, Emilie, additional, Orliaguet, Gilles, additional, Sabau, Lucie, additional, Uhrig, Lynn, additional, Brière, François de la, additional, Jonckheer, Karin, additional, Mission, Jean-Paul, additional, Scordo, Lucia, additional, Couchepin, Caroline, additional, Dadure, Christophe, additional, De la Arena, Pablo, additional, Hertz, Laurent, additional, Pirat, Philippe, additional, Sola, Chrystelle, additional, Bellon, Myriam, additional, Dahmani, Souhayl, additional, Julien-Marsollier, Florence, additional, Michelet, Daphne, additional, Depret-Donatien, Veronique, additional, Lesage, Anne, additional, Kaufmann, Jost, additional, Laschat, Michael, additional, Wappler, Frank, additional, Becke, Karin, additional, Brunner, Lena, additional, Oppenrieder, Karin, additional, Badelt, Gregor, additional, Hochmuth, Karin, additional, Koller, Bernhard, additional, Reil, Anita, additional, Richter, Sebastian, additional, Fischer, Thomas, additional, Diers, Anja, additional, Schorer, Clemens, additional, Weyland, Andreas, additional, Cohausz, Ruth, additional, Kretz, Franz-Josef, additional, Löffler, Michaela, additional, Wilbs, Markus, additional, Hoehne, Claudia, additional, Ulrici, Johanna, additional, Goeters, Christiane, additional, Flinspach, Armin, additional, Klages, Matthias, additional, Lindau, Simone, additional, Messroghli, Leila, additional, Zacharowski, Kai, additional, Eisner, Christoph, additional, Mueller, Thomas, additional, Richter, Daniel, additional, Schäfer, Melanie, additional, Weigand, Markus, additional, Weiterer, Sebastian, additional, Ochsenreiter, Miriam, additional, Schöler, Michael, additional, Terboven, Tom, additional, Eggemann, Isabel, additional, Haussmann, Sascha, additional, Leister, Nicolas, additional, Menzel, Christoph, additional, Trieschmann, Uwe, additional, Yücetepe, Sirin, additional, Keilig, Susanna, additional, Kranke, Peter, additional, Jelting, Yvonne, additional, Baehner, Torsten, additional, Ellerkmann, Richard, additional, Ghamari, Shahab, additional, Neumann, Claudia, additional, Söhle, Martin, additional, Chloropoulou, Pelagia, additional, Ntritsou, Vagia, additional, Papagiannopoulou, Pinelopi, additional, Garini, Eleana, additional, Karafotia, Afroditi, additional, Mammi, Panagoula, additional, Bali, Evangelia, additional, Iordanidou, Despoina, additional, Malisiova, Anna, additional, Polyzoi, Artemis, additional, Tsiotou, Adelais, additional, Sapi, Erzsebet, additional, Székely, Edgar, additional, Kosik, Nandor, additional, Maráczi, Veronika, additional, Schnur, Janos, additional, Csillag, Judit, additional, Gál, János, additional, Göbl, Gergely, additional, Hauser, Balázs, additional, Petróczy, András, additional, Tövisházi, Gyula, additional, Blain, Stuart, additional, Gallagher, Sarah, additional, Harte, Sinead, additional, Jackson, Mandy, additional, Meehan, Emma, additional, Nawoor, Zeenat, additional, O’Hare, Brendan, additional, Ross, Mark, additional, Lerro, Daniela, additional, Astuto, Marinella, additional, Grasso, Chiara, additional, Scalisi, Rita, additional, Frasacco, Giulia, additional, Lenares, Elena, additional, Leone, Roberto, additional, Grazzini, Maurizia, additional, Minardi, Carmelo, additional, Zadra, Nicola, additional, Cinnella, Gilda, additional, Cotoia, Antonella, additional, Galante, Dario, additional, De Lorenzo, Brita, additional, Kuppers, Beate, additional, Bottazzi, Giulia, additional, Caramelli, Fabio, additional, Mondardini, Maria Cristina, additional, Rossetti, Emanuele, additional, Picardo, Sergio, additional, Vittori, Alessandro, additional, Camporesi, Anna, additional, Izzo, Francesca, additional, Calderini, Edoardo, additional, Colantonio, Laura Brigitta, additional, Finamore, Simona Anna, additional, Porro, Giuliana Anna, additional, Bonfiglio, Rachele, additional, Disma, Nicola, additional, Kotzeva, Svetlana, additional, Mattioli, Girolamo, additional, Micalizzi, Camilla, additional, Montaguti, Alessia, additional, Pistorio, Angela, additional, Guddo, Anna, additional, Neba, Gerald Rogan, additional, Favarato, Moreno, additional, Locatelli, Bruno Guido, additional, Maffioletti, Micol, additional, Sonzogni, Valter, additional, Garra, Rossella, additional, Sammartino, Maria, additional, Sbaraglia, Fabio, additional, Cortegiani, Andrea, additional, Moscarelli, Alessandra, additional, Attanasi, Elena, additional, Tesoro, Simonetta, additional, Agapiti, Cristina, additional, Pinzoni, Francesca, additional, Vezzoli, Cesare, additional, Federico, Bilotta, additional, Barzdina, Arta, additional, Straume, Zane, additional, Zundane, Anda, additional, Lukosiene, Laura, additional, Maraulaite, Irena, additional, Razlevice, Ilona, additional, Schmitz, Bernd, additional, Mifsud, Stephanie, additional, Aehling, Carolin, additional, Allison, Celia, additional, De Boer, Rients, additional, Emal, Dina, additional, Stevens, Markus, additional, Buitenhuis, Marielle, additional, de Graaff, Jurgen, additional, De Liefde, Inge, additional, Machotta, Andreas, additional, Scoones, Gail, additional, Staals, Lonneke, additional, Tomas, Jeremy, additional, Van der Knijff-van Dortmont, Anouk, additional, Veldhuizen, Marianne, additional, Alders, David, additional, Schafrat, Eva, additional, Schreiber, Jan, additional, Vermeulen, Petronella Mari, additional, Hendriks, Mark, additional, Lako, Sandra, additional, Voet-Lindner, Marieke, additional, Pieters, Barbe, additional, Scheffer, Gert-Jan, additional, Tielens, Luc, additional, Absalom, Anthony R., additional, Bergsma, Margot, additional, De Ruiter, Joke, additional, Meier, Sascha, additional, Volkers, Martin, additional, Zweers, Tjerk, additional, Beukers, Anne M., additional, Boer, Christa, additional, Dertinger, Jurgen, additional, Numan, Sandra, additional, Van Zaane, Bas, additional, Boerke, Wenche B., additional, Ekiz, Nil, additional, Stensrud, Kristoffer, additional, Drage, Inger Marie, additional, Isern, Erik Ramon, additional, Bartkowska-Sniatkowska, Alicja, additional, Grzeskowiak, Malgorzata, additional, Juzwa-Sobieraj, Magdalena, additional, Rosada-Kurasińska, Jowita, additional, Baranowski, Artur, additional, Jakubowska, Karina, additional, Lewandowska, Dorota, additional, Mierzewska-Schmidt, Magdalena, additional, Sawicki, Piotr, additional, Urban-Lechowicz, Magdalena, additional, Przemyslaw, Pomianek, additional, Zielinska, Marzena, additional, Leal, Teresa, additional, Soares, Maria, additional, Pina, Pedro, additional, Pinho, Sílvia, additional, Patuleia, Maria Domingas, additional, Esteves, Catarina Cruz, additional, Salgado, Helena, additional, Santos, Maria João, additional, Badeti, Rodica, additional, Cindea, Iulia, additional, Oana, Loredana, additional, Gurita, Adriana, additional, Ilie, Luminita, additional, Mocioiu, Gabriel, additional, Tabacaru, Radu, additional, Trante, Irina, additional, Munteanu, Valentin, additional, Morariu, Mihai, additional, Nyíri, Emese, additional, Budic, Ivana, additional, Marjanovic, Vesna, additional, Drašković, Biljana, additional, Pandurov, Marina, additional, Ilic, Jordanka, additional, Mandras, Ana, additional, Rados, Zdenka, additional, Stankovic, Nikola, additional, Suica, Maja, additional, Vasiljevic, Sladjana, additional, Knezevic, Mirjana, additional, Milojevic, Irina, additional, Petrov, Ivana, additional, Racic, Selena Puric, additional, Simic, Dusica, additional, Simic, Irena, additional, Stevic, Marija, additional, Vulicevic, Irena, additional, Bystrica, Banská, additional, Cabanová, Barbora, additional, Hanula, Miloslav, additional, Berger, Jelena, additional, Janjatovic, Darja, additional, Štupnik, Špela Pirtovšek, additional, Méndez, Dolores, additional, Pino, Gema, additional, Rubio, Paloma, additional, Izquierdo, Alberto, additional, López, Silvia, additional, Serrano, Cristina González, additional, Cebrián, Jesús, additional, Peleteiro, Ana, additional, Del Rey de Diego, Pilar, additional, García, Ernesto Martínez, additional, Tormo de las Heras, Carolina, additional, Montero, Pablo Troncoso, additional, Arbona, Celia, additional, Artés, David, additional, Chamizo, Alicia, additional, Serrano, Silvia, additional, Comas, Montserrat Suarez, additional, Escribá, Francisco, additional, Auli, Cristina, additional, Pardo, Osvaldo Pérez, additional, Biddle, Natalia Sierra, additional, Castaño, Ceferina Suárez, additional, Villalobos Rico, María Isabel, additional, Muñoz, Susana Manrique, additional, Martínez, Irene García, additional, Estruch, Nuria Montferrer, additional, Ortíz, Elena Vilardell, additional, Poves-Álvarez, Rodrigo, additional, Kohn, Ivan, additional, Lindestam, Ulf, additional, Reinhard, Jarl, additional, Castellheim, Albert, additional, Sandström, Kerstin, additional, Bengt, Sporre, additional, Dörenberg, Rainer, additional, Frykholm, Peter, additional, Garcia, Maria, additional, Kvarnström, Ann, additional, Pontén, Emma, additional, Bruelisauer, Thomas, additional, Erdoes, Gabor, additional, Kaiser, Heiko, additional, Marchon, Mathias, additional, Riva, Thomas, additional, Seiler, Stefan, additional, Bögli, Yann, additional, Dolci, Mirko, additional, Marcucci, Carine, additional, Pichon, Isabelle, additional, Vutskits, Laszlo, additional, Casutt, Mattias, additional, Hölzle, Martin, additional, Hurni, Thomas, additional, Jöhr, Martin, additional, Malär, Anna-Ursina, additional, Mauch, Jacqueline, additional, Erb, Thomas, additional, Oeinck, Karin, additional, Akin, Mine, additional, Keskin, Gulsen, additional, Senayli, Yesim, additional, Kaya, Guner, additional, Kendigelen, Pinar, additional, Tutuncu, Ayse Çiğdem, additional, Hatipoğlu, Zehra, additional, Özcengiz, Dilek, additional, Erdost, Hale Aksu, additional, Öçmen, Elvan, additional, Olguner, Çimen, additional, Ayanoglu, Hilmi, additional, Dincer, Pelin Corman, additional, Umuroglu, Tumay, additional, Azizoglu, Mustafa, additional, Birbiçer, Handan, additional, Doruk, Nurcan, additional, Sagun, Aslı, additional, Baris, Sibel, additional, Dmytriiev, Dmytro, additional, Kuchi, Sridevi, additional, Masip, Nuria, additional, Brooks, Peter, additional, Hare, Alison, additional, Ahmad, Nargis, additional, Casey, Michelle, additional, De Silva, Sam, additional, Dobby, Nadine, additional, Krishnan, Prakash, additional, Sogbodjor, L. Amaki, additional, Walker, Ellie, additional, Walker, Suellen, additional, King, Stephanie, additional, Nicholson, Katy, additional, Quinney, Michelle, additional, Stevens, Paul, additional, Blevin, Andrew, additional, Giombini, Mariangela, additional, Goonasekera, Chulananda, additional, Adil, Sadia, additional, Bew, Stephanie, additional, Bodlani, Carol, additional, Gilpin, Dan, additional, Jinks, Stephanie, additional, Malarkkan, Nalini, additional, Miskovic, Alice, additional, Pad, Rebecca, additional, Barry, Juliet Wolfe, additional, Abbott, Joy, additional, Armstrong, James, additional, Cooper, Natalie, additional, Crate, Lindsay, additional, Emery, John, additional, James, Kathryn, additional, King, Hannah, additional, Martin, Paul, additional, Catenacci, Stefano Scalia, additional, Bomont, Rob, additional, Smith, Paul, additional, Mele, Sara, additional, Verzelloni, Alessandra, additional, Dix, Philippa, additional, Bell, Graham, additional, Gordeva, Elena, additional, McKee, Lesley, additional, Ngan, Esther, additional, Scheffczik, Jutta, additional, Tan, Li-En, additional, Worrall, Mark, additional, Cassar, Carmel, additional, Goddard, Kevin, additional, Barlow, Victoria, additional, Oshan, Vimmi, additional, Shah, Khairi, additional, Bell, Sarah, additional, Daniels, Lisa, additional, Gandhi, Monica, additional, Pachter, David, additional, Perry, Chris, additional, Robertson, Andrew, additional, Scott, Carmen, additional, Waring, Lynne, additional, Barnes, David, additional, Childs, Sophie, additional, Norman, Joanne, additional, Sunderland, Robin, additional, Julia, Dowell, additional, Prisca, Feijten, additional, Pierre, Harlet, additional, Sarah, Herbineaux, additional, Brigitte, Leva, additional, Benoît, Plichon, additional, and Katalin, Virág, additional

Published
2022
Full Text
View/download PDF

28. Best approximation by diagonal operators in Schatten ideals

Author

Tamara Bottazzi

Subjects
Numerical Analysis, Algebra and Number Theory, Basis (linear algebra), Diagonal, Context (language use), Characterization (mathematics), Hermitian matrix, Separable space, Combinatorics, Discrete Mathematics and Combinatorics, Geometry and Topology, Operator norm, Subspace topology, Mathematics
Abstract

If X is the set of compact or p-Schatten operators over a complex Hilbert separable space H , we study the existence and characterization properties of Hermitian A ∈ X such that | | | A | | | ≤ | | | A + D | | | , for all D ∈ D ( X ) or equivalently | | | A | | | = min D ∈ D ( X ) ⁡ | | | A + D | | | = dist ( A , D ( X ) ) , where D ( X ) is the subspace of diagonal operators of X in any prefixed basis of H and | | | ⋅ | | | is the usual operator norm in each X . We use Birkhoff-James orthogonality as a tool to characterize and develop properties of these operators in each context. We also provide several illustrative examples.

Published
2021
Full Text
View/download PDF

29. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine

Author

Sarah N. Cox, Bruce Y. Lee, Peter J. Hotez, Patrick T. Wedlock, Ulrich Strych, Marie C. Ferguson, Kelly J. O'Shea, Maria Elena Bottazzi, Sheryl S. Siegmund, Sarah M. Bartsch, and Samuel L. Randall

Subjects
medicine.medical_specialty, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Population, Severe disease, medicine.disease_cause, 01 natural sciences, 03 medical and health sciences, 0302 clinical medicine, Pandemic, medicine, Humans, Computer Simulation, 030212 general & internal medicine, 0101 mathematics, Intensive care medicine, education, Pandemics, Coronavirus, education.field_of_study, business.industry, Vaccination, 010102 general mathematics, Public Health, Environmental and Occupational Health, COVID-19, High effectiveness, United States, business, Medical costs, Research Article
Abstract

Introduction During a pandemic, there are many situations in which the first available vaccines may not have as high effectiveness as vaccines that are still under development or vaccines that are not yet ready for distribution, raising the question of whether it is better to go with what is available now or wait. Methods In 2020, the team developed a computational model that represents the U.S. population, COVID-19 coronavirus spread, and vaccines with different possible efficacies (to prevent infection or to reduce severe disease) and vaccination timings to estimate the clinical and economic value of vaccination. Results Except for a limited number of situations, mainly early on in a pandemic and for a vaccine that prevents infection, when an initial vaccine is available, waiting for a vaccine with a higher efficacy results in additional hospitalizations and costs over the course of the pandemic. For example, if a vaccine with a 50% efficacy in preventing infection becomes available when 10% of the population has already been infected, waiting until 40% of the population are infected for a vaccine with 80% efficacy in preventing infection results in 15.6 million additional cases and 1.5 million additional hospitalizations, costing $20.6 billion more in direct medical costs and $12.4 billion more in productivity losses. Conclusions This study shows that there are relatively few situations in which it is worth foregoing the first COVID-19 vaccine available in favor of a vaccine that becomes available later on in the pandemic even if the latter vaccine has a substantially higher efficacy.

Published
2021
Full Text
View/download PDF

31. The Lancet Commission on lessons for the future from the COVID-19 pandemic

Author

Sachs, Jeffrey D, primary, Karim, Salim S Abdool, additional, Aknin, Lara, additional, Allen, Joseph, additional, Brosbøl, Kirsten, additional, Colombo, Francesca, additional, Barron, Gabriela Cuevas, additional, Espinosa, María Fernanda, additional, Gaspar, Vitor, additional, Gaviria, Alejandro, additional, Haines, Andy, additional, Hotez, Peter J, additional, Koundouri, Phoebe, additional, Bascuñán, Felipe Larraín, additional, Lee, Jong-Koo, additional, Pate, Muhammad Ali, additional, Ramos, Gabriela, additional, Reddy, K Srinath, additional, Serageldin, Ismail, additional, Thwaites, John, additional, Vike-Freiberga, Vaira, additional, Wang, Chen, additional, Were, Miriam Khamadi, additional, Xue, Lan, additional, Bahadur, Chandrika, additional, Bottazzi, Maria Elena, additional, Bullen, Chris, additional, Laryea-Adjei, George, additional, Ben Amor, Yanis, additional, Karadag, Ozge, additional, Lafortune, Guillaume, additional, Torres, Emma, additional, Barredo, Lauren, additional, Bartels, Juliana G E, additional, Joshi, Neena, additional, Hellard, Margaret, additional, Huynh, Uyen Kim, additional, Khandelwal, Shweta, additional, Lazarus, Jeffrey V, additional, and Michie, Susan, additional

Published
2022
Full Text
View/download PDF

32. A novel multi-epitope recombinant protein elicits an antigen-specific CD8+ T cells response in Trypanosoma cruzi-infected mice

Author

González-López, Cristina, primary, Chen, Wen-Hsiang, additional, Alfaro-Chacón, Andrea, additional, Villanueva-Lizama, Liliana E., additional, Rosado-Vallado, Miguel, additional, Ramirez-Sierra, Maria Jesús, additional, Teh-Poot, Christian F., additional, Pollet, Jeroen, additional, Asojo, Oluwatoyin, additional, Jones, Kathryn M., additional, Hotez, Peter J., additional, Elena Bottazzi, Maria, additional, and Cruz-Chan, Julio Vladimir, additional

Published
2022
Full Text
View/download PDF

37. Vaccines and therapeutics for immunocompromised patients with COVID-19

Author

Shmuel Shoham, Carolina Batista, Yanis Ben Amor, Onder Ergonul, Mazen Hassanain, Peter Hotez, Gagandeep Kang, Jerome H. Kim, Bhavna Lall, Heidi J. Larson, Denise Naniche, Timothy Sheahan, Nathalie Strub-Wourgaft, Samba O. Sow, Annelies Wilder-Smith, Prashant Yadav, and Maria Elena Bottazzi

Subjects
General Medicine
Published
2023
Full Text
View/download PDF

38. Basic of machine learning and deep learning in imaging for medical physicists

Author

Luca Bottazzi, N. Maffei, Lidia Strigari, Luigi Manco, S. Strolin, and Sara Vichi

Subjects
Diagnostic Imaging, Information retrieval, Query string, business.industry, Computer science, Deep learning, Biophysics, General Physics and Astronomy, General Medicine, Automation, 030218 nuclear medicine & medical imaging, Machine Learning, Clinical Practice, Medical physicist, 03 medical and health sciences, Deep Learning, 0302 clinical medicine, Artificial Intelligence, 030220 oncology & carcinogenesis, Radiology, Nuclear Medicine and imaging, Artificial intelligence, business, Algorithms
Abstract

The manuscript aims at providing an overview of the published algorithms/automation tool for artificial intelligence applied to imaging for Healthcare. A PubMed search was performed using the query string to identify the proposed approaches (algorithms/automation tools) for artificial intelligence (machine and deep learning) in a 5-year period. The distribution of manuscript in the various disciplines and the investigated image types according to the AI approaches are presented. The limitation and opportunity of AI application in the clinical practice or in the next future research is discussed.

Published
2021
Full Text
View/download PDF

39. Association of high-risk coronary atherosclerosis at CCTA with clinical and circulating biomarkers: Insight from CAPIRE study

Author

Edoardo Conte, Daniele Andreini, Marco Magnoni, Serge Masson, Saima Mushtaq, Sergio Berti, Mauro Canestrari, Giancarlo Casolo, Domenico Gabrielli, Roberto Latini, Paolo Marraccini, Tiziano Moccetti, Maria Grazia Modena, Gianluca Pontone, Marco Gorini, Aldo P. Maggioni, Attilio Maseri, A. Maseri, D. Andreini, S. Berti, M. Canestrari, G. Casolo, D. Gabrielli, R. Latini, M. Magnoni, P. Marraccini, S. Masson, T. Moccetti, M.G. Modena, G. Pontone, F. Gaspari, S. Ferrari, A. Cannata, N. Stucchi, M. Fois, R. Bernasconi, G. Balconi, T. Vago, T. Letizia, B. Bottazzi, R. Leone, I. Suliman, M. Sommaruga, P. Gremigni, R. Olivieri, L. Pennacchietti, M. Magnacca, M.G. Rossi, E. Pasotti, A. Clemente, S. Mushtaq, E. Mauro, R. Rossi, F. Pigazzani, L. Faggioni, M. Ciardetti, and M. Puppato

Subjects
Male, Computed Tomography Angiography, Coronary Artery Disease, 030204 cardiovascular system & hematology, Coronary Angiography, Logistic regression, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Risk Factors, Prevalence, Medicine, Prospective Studies, Age Factors, Coronary ct angiography, Middle Aged, Prognosis, Inflammatory biomarkers, Plaque, Atherosclerotic, Serum Amyloid P-Component, C-Reactive Protein, Italy, Cohort, Female, Cardiology and Cardiovascular Medicine, Coronary plaque, Clinical risk factor, medicine.medical_specialty, Cardiac computed tomography, Risk Assessment, 03 medical and health sciences, Sex Factors, Predictive Value of Tests, Diabetes mellitus, Internal medicine, Multidetector Computed Tomography, Humans, Radiology, Nuclear Medicine and imaging, Coronary atherosclerosis, Aged, Glycated Hemoglobin, Inflammation, business.industry, High-risk plaque features, medicine.disease, Cardiovascular prevention, Circulating biomarkers, Cross-Sectional Studies, business, Biomarkers
Abstract

Background High-risk coronary atherosclerosis features evaluated coronary CT angiography (CCTA) were suggested to have a prognostic role. The present study aimed to evaluate the association of circulating biomarkers with high-risk plaque features assessed by CCTA. Methods A consecutive cohort of subjects who underwent CCTA because of suspected CAD was screened for inclusion in the CAPIRE study. Based on risk factors (RF) burden patients were defined as having a low clinical risk (0–1 RF with the exclusion of patients with diabetes mellitus as single RF) or an high clinical risk (≥3 RFs). In all patients, measurement of inflammatory biomarkers and CCTA analysis focused on high-risk plaque features were performed. Univariate and multivariate logistic regression analysis were used to evaluate the relationship between clinical and biological variables with CCTA advanced plaque features. Results 528 patients were enrolled in CAPIRE study. Older age and male sex appeared to be predictors of qualitative high-risk plaque features and associated with the presence of elevated total, non-calcified and low-attenuation plaque volume. Among circulating biomarkers only hs-CRP was found to be associated with qualitative high-risk plaque features (OR 2.02, p = 0.004 and 2.02, p = 0.012 for LAP and RI > 1.1, respectively) with borderline association with LAP-Vol (OR 1.52, p = 0.076); HbA1c and PTX-3 resulted to be significantly associated with quantitative high-risk plaque features (OR 1.71, p = 0.003 and 1.04, p = 0.002 for LAP-Vol, respectively). Conclusions Our results support the association between inflammatory biomarkers (hs-CRP, PTX- 3), HbA1c and high-risk atherosclerotic features detected by CCTA. Male sex and older age are significant predictors of high-risk atherosclerosis.

Published
2021
Full Text
View/download PDF

40. Vaccination with chimeric protein induces protection in murine model against ascariasis

Author

Maria Elena Bottazzi, Joseane Camilla de Castro, Bin Zhan, Denise Silva Nogueira, Fabrício Marcus Silva Oliveira, Daniella Castanheira Bartholomeu, Laila Viana de Almeida, Lilian Lacerda Bueno, João Luís Reis-Cunha, Peter J. Hotez, Ricardo Toshio Fujiwara, Luísa Mourão Dias Magalhães, and Mariana Santos Cardoso

Subjects
Recombinant Fusion Proteins, 030231 tropical medicine, Monophosphoryl Lipid A, Epitope, Mice, 03 medical and health sciences, 0302 clinical medicine, Antigen, medicine, Animals, 030212 general & internal medicine, Ascaris suum, B cell, Ascariasis, Mice, Inbred BALB C, General Veterinary, General Immunology and Microbiology, biology, Ascaris, Vaccination, Public Health, Environmental and Occupational Health, biology.organism_classification, Fusion protein, Virology, Disease Models, Animal, Infectious Diseases, medicine.anatomical_structure, Antigens, Helminth, Molecular Medicine, Female
Abstract

An estimated 400 million people are infected by parasites of the genus Ascaris and the existing control measures are inefficient. Vaccine development using B cell antigens is a promising strategy for increased protection against this parasite. The present study aimed at developing a chimeric protein capable of conferring protection against infection by Ascaris sp. For this purpose, we performed B-cell epitope predictions on previously described vaccine candidate proteins from Ascaris suum and the corresponding peptides were used to construct a chimeric protein. Female BALB / c mice were immunized subcutaneously in three doses at 10 day intervals with a vaccine formulation comprised of the chimeric protein together with monophosphoryl lipid A (MPLA). Control groups included protein alone, MPLA, or PBS. After challenge infection, animals vaccinated with chimeric protein plus MPLA showed a reduction of 73.54% of larval load in the lung compared to control group animals. Animals immunized with chimeric protein plus MPLA also display higher IgG response and a reduction in lung inflammation. Our study highlights how chimeric proteins containing more than one B cell epitope can enhance immune protection against helminthic infection and offer new approaches to the development of Ascaris vaccines.

Published
2021
Full Text
View/download PDF

42. Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

Author

Pollet, Jeroen, primary, Strych, Ulrich, additional, Chen, Wen-Hsiang, additional, Versteeg, Leroy, additional, Keegan, Brian, additional, Zhan, Bin, additional, Wei, Junfei, additional, Liu, Zhuyun, additional, Lee, Jungsoon, additional, Kundu, Rahki, additional, Adhikari, Rakesh, additional, Poveda, Cristina, additional, Jose Villar, Maria, additional, Rani Thimmiraju, Syamala, additional, Lopez, Brianna, additional, Gillespie, Portia M., additional, Ronca, Shannon, additional, Kimata, Jason T., additional, Reers, Martin, additional, Paradkar, Vikram, additional, Hotez, Peter J., additional, and Elena Bottazzi, Maria, additional

Published
2022
Full Text
View/download PDF

43. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement

Author

Ulrich Strych, Peter J. Hotez, Anurodh S. Agrawal, Jeroen Pollet, Lanying Du, Shibo Jiang, Wen-Hsiang Chen, Chien-Te K Tseng, Xinrong Tao, Bi Hung Peng, Abdullah Algaissi, Maria Elena Bottazzi, and Sara Lustigman

Subjects
viruses, medicine.medical_treatment, coronavirus, Aluminum Hydroxide, Antibodies, Viral, medicine.disease_cause, law.invention, Mice, 0302 clinical medicine, law, vaccine, 030212 general & internal medicine, skin and connective tissue diseases, Neutralizing antibody, Coronavirus, Mice, Inbred BALB C, Vaccines, Synthetic, biology, Viral Vaccine, Viral Load, eosinophil infiltration, Recombinant Proteins, Infectious Diseases, Spike Glycoprotein, Coronavirus, Vaccines, Subunit, Recombinant DNA, Molecular Medicine, Female, Antibody, Coronavirus Infections, Viral load, Adjuvant, COVID-19 Vaccines, Pneumonia, Viral, 030231 tropical medicine, severe acute respiratory syndrome, Article, Virus, Betacoronavirus, 03 medical and health sciences, Immune system, Protein Domains, medicine, Animals, Humans, Pandemics, General Veterinary, General Immunology and Microbiology, SARS-CoV-2, fungi, Public Health, Environmental and Occupational Health, COVID-19, Viral Vaccines, Antibodies, Neutralizing, Virology, respiratory tract diseases, body regions, biology.protein, recombinant protein
Abstract

Highlights • A SARS-CoV recombinant protein-based receptor binding domain (RBD) vaccine on alum provides high neutralizing antibody titers eliciting 100% protection (survival) against homologous SARS CoV virus challenge. • A SARS-CoV RBD vaccine on alum prevents pulmonary cellular infiltrates upon virus challenge. • A SARS-CoV RBD vaccine on alum greatly reduces lung eosinophils compared to a vaccine comprised of the SARS-CoV S protein. • The SARS-CoV RBD vaccine on alum is being developed as a human vaccine., We developed a severe acute respiratory syndrome (SARS) subunit recombinant protein vaccine candidate based on a high-yielding, yeast- engineered, receptor-binding domain (RBD219-N1) of the SARS beta-coronavirus (SARS-CoV) spike (S) protein. When formulated with Alhydrogel®, RBD219-N1 induced high-level neutralizing antibodies against both pseudotyped virus and a clinical (mouse-adapted) isolate of SARS-CoV. Here, we report that mice immunized with RBD219-N1/Alhydrogel® were fully protected from lethal SARS-CoV challenge (0% mortality), compared to ∼ 30% mortality in mice immunized with the SARS S protein formulated with Alhydrogel®, and 100% mortality in negative controls. An RBD219-N1 formulation with Alhydrogel® was also superior to the S protein, unadjuvanted RBD, and AddaVax (MF59-like adjuvant)-formulated RBD in inducing specific antibodies and preventing cellular infiltrates in the lungs upon SARS-CoV challenge. Specifically, a formulation with a 1:25 ratio of RBD219-N1 to Alhydrogel® provided high neutralizing antibody titers, 100% protection with non-detectable viral loads with minimal or no eosinophilic pulmonary infiltrates. As a result, this vaccine formulation is under consideration for further development against SARS-CoV and potentially other emerging and re-emerging beta-CoVs such as SARS-CoV-2.

Published
2020
Full Text
View/download PDF

44. Spaces of measurable functions on the Levi-Civita field

Author

Emanuele Bottazzi

Subjects
Pure mathematics, Generalized function, Lebesgue measure, Continuous function, Measurable function, General Mathematics, 010102 general mathematics, Duality (mathematics), Banach space, Hilbert space, 010103 numerical & computational mathematics, 01 natural sciences, Measure (mathematics), symbols.namesake, symbols, 0101 mathematics, Mathematics
Abstract

We introduce the ℒ p spaces of measurable functions whose p th power is summable with respect to the uniform measure over the Levi-Civita field. These spaces are the counterparts of the real L p spaces based upon the Lebesgue measure. Nevertheless, they lack some properties of the L p spaces: for instance, the ℒ p spaces are not sequentially complete with respect to the p -norm. This motivates the study of the completions of the ℒ p spaces with respect to strong convergence, denoted by ℒ s p . It turns out that the ℒ s p spaces are Banach spaces and that it is possible to define an inner product over ℒ s 2 , thus making it a Hilbert space. Despite these positive results, these spaces are still not rich enough to represent every real continuous function. For this reason, we settle upon the representation of real measurable functions as sequences of measurable functions in ℛ that weakly converge in measure. We also define a duality between measurable functions and representatives of continuous functions. This duality enables the study of some measurable functions that represent real distributions. We focus our discussion on the representatives of the Dirac distribution and on the well-known problem of the product between the Dirac and the Heaviside distribution, and we show that the solution obtained with measurable functions over ℛ is consistent with the result obtained with other nonlinear generalized functions.

Published
2020
Full Text
View/download PDF

45. Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania Vaccine Candidate

Author

Rakhi Tyagi Kundu, Wen-Hsiang Chen, Mun Peak Nyon, Amadeo B. Biter, Peter J. Hotez, Ulrich Strych, Maria Elena Bottazzi, Mohan Vivekanandan Poongavanam, and Zhuyun Liu

Subjects
Pharmaceutical Science, Saccharomyces cerevisiae, 02 engineering and technology, 030226 pharmacology & pharmacy, Microbiology, law.invention, Mice, 03 medical and health sciences, 0302 clinical medicine, Cutaneous leishmaniasis, law, medicine, Animals, Parasite hosting, Leishmania major, Salivary Proteins and Peptides, Leishmaniasis Vaccines, biology, Tropical disease, 021001 nanoscience & nanotechnology, medicine.disease, biology.organism_classification, Leishmania, Yeast, Sandfly, Phlebotomus, Recombinant DNA, Insect Proteins, 0210 nano-technology
Abstract

Cutaneous leishmaniasis is a neglected tropical disease caused by the parasite Leishmania and transmitted by sandflies. It has become a major health problem in many tropical and subtropical countries, especially in regions of conflict and political instability. Currently, there are only limited drug treatments and no available licensed vaccine; thus, the need for more therapeutic interventions remains urgent. Previously, a DNA vaccine encoding a 15 kDa sandfly (Phlebotomus papatasi) salivary protein (PpSP15) and recombinant nonpathogenic Leishmania tarentolae secreting PpSP15 have been shown to induce protective immunity against Leishmania major in mice, demonstrating that PpSP15 is a promising vaccine candidate. In this study, we developed a fermentation process in yeast with a yield of ~1g PpSP15/L and a scalable purification process consisting of only 2 chromatographic purification steps with high binding capacity for PpSP15, suggesting that PpSP15 can be produced economically. The biophysical/biochemical analysis of the purified PpSP15 indicated that the protein was of high purity (>97%) and conformationally stable between pH 4.4 and 9.0. More importantly, the recombinant protein had a defined structure similar to that of the related PdSP15 from Phlebotomus duboscqi, implying the suitability of the yeast expression system for producing a correctly folded PpSP15.

Published
2020
Full Text
View/download PDF

46. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission

Author

Jorge Abelardo Falcón-Lezama, Elizabeth A. Mitgang, Pierre Buekens, Ulrich Strych, Sheba Meymandi, Lindsey Asti, Maria Elena Bottazzi, Owen J. Stokes-Cawley, Patrick T. Wedlock, Sarah M. Bartsch, Peter J. Hotez, and Bruce Y. Lee

Subjects
Chagas disease, Pediatrics, medicine.medical_specialty, Cost-Benefit Analysis, Uncertainty interval, Article, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, 030225 pediatrics, medicine, Humans, Chagas Disease, 030212 general & internal medicine, Mexico, health care economics and organizations, Vaccines, General Veterinary, General Immunology and Microbiology, business.industry, Transmission (medicine), Vaccination, Public Health, Environmental and Occupational Health, Infant, Diagnostic test, medicine.disease, Infant mortality, Latin America, Infectious Diseases, Molecular Medicine, Female, Pregnant Women, Congenital transmission, business
Abstract

BACKGROUND: Currently, there are no solutions to prevent congenital transmission of Chagas disease during pregnancy, which affects 1–40% of pregnant women in Latin America and is associated with a 5% transmission risk. With therapeutic vaccines under development, now is the right time to determine the economic value of such a vaccine to prevent congenital transmission. METHODS: We developed a computational decision model that represented the clinical outcomes and diagnostic testing strategies for an infant born to a Chagas-positive woman in Mexico and evaluated the impact of vaccination. RESULTS: Compared to no vaccination, a 25% efficacious vaccine averted 125 [95% uncertainty interval (UI): 122–128] congenital cases, 1.9 (95% UI: 1.6–2.2) infant deaths, and 78 (95% UI: 66–91) DALYs per 10,000 infected pregnant women; a 50% efficacious vaccine averted 251 (95% UI: 248–254) cases, 3.8 (95% UI: 3.6–4.2) deaths, and 160 (95% UI: 148–171) DALYs; and a 75% efficacious vaccine averted 376 (95% UI: 374–378) cases, 5.8 (95% UI: 5.5–6.1) deaths, and 238 (95% UI: 227–249) DALYs. A 25% efficacious vaccine was cost-effective (incremental cost-effectiveness ratio

Published
2020
Full Text
View/download PDF

47. The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age

Author

So Yoon Sim, Bruce Y. Lee, Sarah M. Bartsch, Maria Elena Bottazzi, Peter J. Hotez, Owen J. Stokes-Cawley, and Lindsey Asti

Subjects
Adult, Adolescent, Epidemiology, Cost-Benefit Analysis, Target population, 01 natural sciences, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, Humans, Medicine, 030212 general & internal medicine, 0101 mathematics, health care economics and organizations, Zika Virus Infection, Potential risk, business.industry, Risk of infection, Vaccination, 010102 general mathematics, Public Health, Environmental and Occupational Health, Clinical course, Middle Aged, Vaccine efficacy, Markov Chains, Childbearing age, Income level, Female, Quality-Adjusted Life Years, Americas, business, Demography
Abstract

Introduction With Zika vaccine candidates under development and women of childbearing age being the primary target population, now is the time to map the vaccine (e.g., efficacy and duration of protection) and vaccination (e.g., cost) characteristic thresholds at which vaccination becomes cost effective, highly cost effective, and cost saving. Methods A Markov model was developed (to represent 2019 circumstances, US$ and INT$, Region of the Americas) to simulate a woman of childbearing age and the potential risk and clinical course of a Zika infection. Results Compared with no vaccination, vaccination was cost effective (incremental cost–effectiveness ratio: US$1,254–$82,900/disability-adjusted life years averted) when the risk of infection was ≥0.05%–0.08% (varying with country income), vaccine efficacy was ≥25%, and vaccination cost was US$1–$7,500 (INT$5–$10,000 depending on country income level). Vaccination was dominant (i.e., saved costs and provided beneficial health effects) when the infection risk was ≥0.1% for a vaccine efficacy ≥75% and when the infection risk was ≥0.5% for a vaccine efficacy ≥25%, for scenarios where vaccination conferred a 1-year duration of protection and cost ≤$200. In some cases, the vaccine was cost effective when the risk was as low as 0.015%, the cost was as high as $7,500 (INT$10,000), the efficacy was as low as 25%, and the duration of protection was 1 year. Conclusions The thresholds at which vaccination becomes cost effective and cost saving can provide targets for Zika vaccine development and implementation.

Published
2020
Full Text
View/download PDF

49. The attitude towards organ donation: Differences between students of medicine and nursing. A preliminary study at Unizkm - Catholic University “Our Lady of Good Counsel” of Tirana

Author

Ruta, Federico, primary, Ferrara, Paolo, additional, Terzoni, Stefano, additional, Dal Mas, Francesca, additional, Bottazzi, Andrea, additional, Prendi, Emanuela, additional, Dragusha, Pranvera, additional, Delli Poggi, Alessandro, additional, and Cobianchi, Lorenzo, additional

Published
2022
Full Text
View/download PDF

50. Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate

Author

Chen, Wen-Hsiang, primary, Pollet, Jeroen, additional, Strych, Ulrich, additional, Lee, Jungsoon, additional, Liu, Zhuyun, additional, Kundu, Rakhi Tyagi, additional, Versteeg, Leroy, additional, Villar, Maria Jose, additional, Adhikari, Rakesh, additional, Wei, Junfei, additional, Poveda, Cristina, additional, Keegan, Brian, additional, Bailey, Aaron Oakley, additional, Chen, Yi-Lin, additional, Gillespie, Portia M., additional, Kimata, Jason T., additional, Zhan, Bin, additional, Hotez, Peter J., additional, and Bottazzi, Maria Elena, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results